$IBRX News

HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target

ImmunityBio Presents Data At American Society Of Clinical Oncology Annual Meeting About Its Phase 3 Studies In Advanced Non-Small Cell Lung Cancer

ImmunityBio Announces Preliminary Results From News Economic Analysis Showing That Anktiva Plus Bacillus Calmette–Guérin Achieved A Lower Cost Per Sustained Complete Responder

ImmunityBio Announces New Survey Data Showing Diverse Treatment Preferences And Priorities Of Patients With Bacillus Calmette–Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer

BTIG Reiterates Buy on ImmunityBio, Maintains $12 Price Target

ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout

HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target

Reported Earlier, ImmunityBio Says FDA Accepted ANKTIVA Plus Bacillus Calmette-Guerin Filing For Papillary Non-Muscle Invasive Bladder Cancer Following Workshop Support And National Comprehensive Cancer Network Guidance

ImmunityBio Announces Results From Two ITC Analyses Presented At 2026 AUA Annual Meeting Evaluating Nogapendekin Alfa inbakicept-pmln Plus BCG

ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership

ImmunityBio Secures Five US Patents Covering Combination Of IL-15 Receptor Agonist ANKTIVA With Bacillus Calmette-Guérin For Treatment Of Cancer

Reported Saturday, ImmunityBio Secures Exclusive US Rights To Tokyo-172 BCG After Phase 3 Trial Shows Non-Inferior Efficacy To TICE BCG

ImmunityBio Stock Drops After Earnings Miss Despite Anktiva Momentum

ImmunityBio Inc (NASDAQ:IBRX) Q1 Revenue Beat Overshadowed by Wider Losses and Stock Decline

UPDATE: ImmunityBio Q1 Adj. EPS $(0.08) Misses $(0.07) Estimate, Sales $44.206M Beat $43.069M Estimate

ImmunityBio Q1 EPS $(0.62) Misses $(0.07) Estimate, Sales $44.206M Beat $43.069M Estimate

Why ImmunityBio Stock Is Surging On Wednesday?

ImmunityBio To Present New Treatment Comparison Results Evaluating ANKTIVA Plus BCG Versus Nadofaragene Firadenovec-Vncg And TAR-200 In Patients With NMIBC CIS, With Or Without Papillary Disease, At AUA 2026

ImmunityBio Stock Rises As ANKTIVA Launches in Saudi Arabia

ImmunityBio Expands Commercial Access For ANKTIVA Bladder And Lung Cancer Treatment To Saudi Arabia